Neoadjuvant atezolizumab plus chemotherapy supported for early TNBC

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 20 / Springer Healthcare

Neoadjuvant atezolizumab plus chemotherapy supported for early TNBC

University of Munich, Germany

Oncology Cancer Immunotherapy Breast Cancer ESMO-2020

Description

Nadia Harbeck presents the IMpassion031 study showing improved pathological complete responses with the addition of atezolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.